Abbott Completes Acquisition of Evalve.

Evalve’s innovative valve repair technology gives us the potential to supply new treatment plans for millions of patients with mitral regurgitation around the world, stated Robert Hance, senior vice president, vascular, Abbott. This acquisition complements Abbott’s industry-leading pipeline and strong vascular devices portfolio, which currently keeps leadership positions in medication eluting and bare metal stent segments. Abbott acquired the remaining outstanding collateral of Evalve that it didn’t already very own for an upfront payment of $320 million, and also a $90 million payment if certain regulatory milestones are fulfilled. Continue reading